Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences

Rhea-AI Summary

Infinity Pharmaceuticals (NASDAQ: INFI) announced participation in two upcoming virtual healthcare conferences. The Wells Fargo Virtual Healthcare Conference will feature a fireside chat on September 9, 2021, at 2:40 PM ET, with 1-on-1 meetings on September 9-10. The H.C. Wainwright 23rd Annual Global Investment Conference will present on-demand on September 13, 2021, at 7 AM ET, with 1-on-1 meetings from September 13-15. Presentations will be available on Infinity's website for 30 days.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that the Company will participate in Wells Fargo’s Virtual Healthcare Conference and H.C. Wainwright’s 23^rd Annual Global Investment Conference being held virtually.

Presentation details can be found below:

• Wells Fargo Virtual Healthcare Conference
  Format: Fireside chat and 1-on-1 meetings
  Date and Time: Fireside chat September 9 ^th at 2:40pm ET; 1-on-1 meetings September 9-10
  Webcast Link: https://kvgo.com/wells-fargo/infinity-pharmaceuticals-sept-2021

• H.C. Wainwright Virtual 23^rd Annual Global Investment Conference
  Format: On demand presentation and 1-on-1 meetings
  Date and Time: Presentation available Monday, September 13 ^th 7am ET; 1-on-1 meetings September 13-15
  Registration Link

The presentations and archived webcasts can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.

About Infinity and Eganelisib

Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo^® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in front-line TNBC and in combination with Tecentriq and Avastin^® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil^® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.
Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin^® is a registered trademark of Genentech, Inc.
Doxil^® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005247/en/

Investor Relations:

Irina Koffler

LifeSci Advisors, LLC

646-970-4681

ikoffler@lifesciadvisors.com

Source: Infinity Pharmaceuticals, Inc.

FAQ

What is the schedule for Infinity Pharmaceuticals at the Wells Fargo Virtual Healthcare Conference?

Infinity Pharmaceuticals will participate in the Wells Fargo Virtual Healthcare Conference on September 9, 2021, with a fireside chat at 2:40 PM ET and 1-on-1 meetings on September 9-10.

When will Infinity Pharmaceuticals present at the H.C. Wainwright Global Investment Conference?

Infinity Pharmaceuticals will have an on-demand presentation available on September 13, 2021, at 7 AM ET, with 1-on-1 meetings from September 13-15.

Where can I access the presentations by Infinity Pharmaceuticals after the conferences?

The presentations and archived webcasts will be accessible on Infinity's website for 30 days following the events.

What is eganelisib and its significance in Infinity Pharmaceuticals' pipeline?

Eganelisib is an oral immuno-oncology therapeutic developed by Infinity Pharmaceuticals that targets immune suppression in cancer, currently being evaluated in various clinical studies.